Table 1 Clinical and demographic characteristics of Behçet’s disease without and with intestinal involvement.
From: Identification of genetic susceptibility loci for intestinal Behçet’s disease
BD without intestinal involvement (n = 238) | Intestinal BD (n = 295) | |
|---|---|---|
Sex, male (%) | 62 (26.1) | 135 (45.8) |
Mean age (years) | 41.8 ± 11.8 | 44.3 ± 12.3 |
Mean age at diagnosis (years) | 35.5 ± 10.8 | 40.1 ± 11.8 |
Mean disease duration (years) | 5.9 ± 6.9 | 7.5 ± 5.7 |
HLA-B51 positivity (%) A | 83/226 (36.7) | 23/102 (22.5)* |
Clinical manifestations (%) | ||
Oral ulcers | 238 (100) | 273 (92.5) |
Genital ulcers | 212 (89.1) | 154 (52.2) |
Eye lesions | 76 (31.9) | 52 (17.6) |
Skin lesions | 219 (92.0) | 192 (65.1) |
Arthritis/arthralgia | 134 (56.3) | 158 (53.6) |
Vascular lesions | 10 (4.2) | 11 (3.7) |
Central nervous system lesions | 5 (2.1) | 5 (1.7) |
Epididymitis | 3 (1.3) | 0 |
Intestinal complications (%) | ||
Perforation | 0 (0.0) | 28 (9.5) |
Fistula | 0 (0.0) | 26 (8.8) |
Stricture | 0 (0.0) | 25 (8.5) |
Abscess | 0 (0.0) | 13 (4.4) |
Medication use (%) | ||
5-aminosalicylic acid/ sulfasalazine | 0 (0.0) | 288 (97.6) |
Corticosteroids | 124 (52.1) | 136 (46.1) |
Azathiopurine/6-mercaptopurine | 24 (10.1) | 107 (36.3) |
Anti-TNF agent | 0 (0.0) | 8 (2.7) |
